Logo

GSK’s GSK5764227 (GSK’227) Gets the US FDA’s Breakthrough Therapy Designation for r/r Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Share this

GSK’s GSK5764227 (GSK’227) Gets the US FDA’s Breakthrough Therapy Designation for r/r Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Shots:

  • The US FDA has granted BTD to GSK’227, a B7-H3-targeted ADC, for ES-SCLC with disease progression on or after Pt-based CT, and GSK holds exclusive development and commercialization rights worldwide (excluding China) from Hansoh Pharma
  • The BTD was based on early clinical evidence from the P-I (ARTEMIS-001) study assessing safety, tolerability & preliminary anti-tumor activity in r/r ES-SCLC individuals (n>200), conducted by Hansoh Pharma
  • GSK’227 aka. HS-20093 is now being developed by Hansoh Pharma. An ongoing P-I/II study for various solid tumors in China. Additionally, GSK plans to initiate a P-I/II global study in H2’24 to support a registrational pathway for GSK’227

Ref: GSK | Image: GSK

Related News:- GSK Reports the US FDA’s Expanded Approval of Jemperli Plus Chemotherapy for Treating Endometrial Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Dipanshu Dixit

A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions